FBIO insider transaction filings
Fortress Biotech, Inc. — 41 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-24. Screen FBIO transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Jin David — Chief Financial Officer | 1 | — | — | 1 |
Recent Form 4 filings — Fortress Biotech, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-24 | 4 | Jin David — Chief Financial Officer | Grant/award (A): 400,000 @ $0 | EDGAR |
| 2026-04-01 | 4 | Jin David — Chief Financial Officer | Grant/award (A): 2,967 @ $2.18 | EDGAR |
| 2026-03-20 | 4 | ROSENWALD LINDSAY A MD — PRESIDENT, CEO & CHAIRMAN, Director, 10% owner | Grant/award (A): 475,424 @ $0 | EDGAR |
| 2026-03-20 | 4 | WEISS MICHAEL S — Executive Vice Chairman, Director | Grant/award (A): 475,424 @ $0 | EDGAR |
| 2026-01-05 | 4 | Lorenz Kevin — Director | Grant/award (A): 27,322 @ $0 | EDGAR |
| 2026-01-05 | 4 | Klein Dov — Director | Grant/award (A): 27,322 @ $0 | EDGAR |
| 2026-01-05 | 4 | Harvey Jimmie — Director | Grant/award (A): 27,322 @ $0 | EDGAR |
| 2026-01-05 | 4 | Hoenlein Malcolm — Director | Grant/award (A): 27,322 @ $0 | EDGAR |
| 2026-01-05 | 4 | LOBELL J JAY — Director | Grant/award (A): 27,322 @ $0 | EDGAR |
| 2025-10-02 | 4 | Jin David — Chief Financial Officer | Grant/award (A): 2,711 @ $1.31 | EDGAR |
| 2025-04-01 | 4 | Jin David — Chief Financial Officer | Grant/award (A): 5,000 @ $1.22 | EDGAR |
| 2025-01-03 | 4 | Klein Dov — Director | Grant/award (A): 49,383 @ $0 | EDGAR |
| 2025-01-03 | 4 | Lu Lucy — Director | Grant/award (A): 49,383 @ $0 | EDGAR |
| 2025-01-03 | 4 | Harvey Jimmie — Director | Grant/award (A): 49,383 @ $0 | EDGAR |
| 2025-01-03 | 4 | Lorenz Kevin — Director | Grant/award (A): 49,383 @ $0 | EDGAR |
| 2025-01-03 | 4 | ROSENWALD LINDSAY A MD — PRESIDENT, CEO & CHAIRMAN, Director, 10% owner | Grant/award (A): 454,153 @ $0 | EDGAR |
| 2025-01-03 | 4 | Hoenlein Malcolm — Director | Grant/award (A): 49,383 @ $0 | EDGAR |
| 2025-01-03 | 4 | LOBELL J JAY — Director | Grant/award (A): 49,383 @ $0 | EDGAR |
| 2025-01-03 | 4 | WEISS MICHAEL S — Executive Vice Chairman, Director | Grant/award (A): 454,153 @ $0 | EDGAR |
| 2024-12-23 | 4 | Jin David — Chief Financial Officer | Grant/award (A): 1,000,000 @ $0 | EDGAR |
| 2024-10-01 | 4 | Jin David — Chief Financial Officer | Grant/award (A): 2,625 @ $1.23 | EDGAR |
| 2024-09-25 | 4 | ROSENWALD LINDSAY A MD — PRESIDENT, CEO & CHAIRMAN, Director, 10% owner | Purchase (P): 763,359 @ $1.84 · Purchase (P): 763,359 (derivative) @ $0.12 | EDGAR |
| 2024-07-15 | 4 | ROSENWALD LINDSAY A MD — President, CEO & Chairman, Director, 10% owner | Purchase (P): 5,000 @ $7.48 | EDGAR |
| 2024-07-12 | 4 | Jin David — Chief Financial Officer | Purchase (P): 500 @ $7.50 | EDGAR |
| 2024-07-11 | 4 | ROSENWALD LINDSAY A MD — President, CEO & Chairman, Director, 10% owner | Purchase (P): 5,000 @ $7.39 | EDGAR |
| 2024-07-10 | 4 | ROSENWALD LINDSAY A MD — President, CEO & Chairman, Director, 10% owner | Purchase (P): 5,000 @ $7.35 | EDGAR |
| 2024-07-01 | 4 | ROSENWALD LINDSAY A MD — President, CEO & Chairman, Director, 10% owner | Purchase (P): 20,000 @ $1.64 | EDGAR |
| 2024-05-20 | 4 | ROSENWALD LINDSAY A MD — President, CEO & Chairman, Director, 10% owner | Purchase (P): 10,000 @ $1.76 | EDGAR |
| 2024-05-20 | 4 | Klein Dov — Director | Sale (S): 10,000 @ $1.89 | EDGAR |
| 2024-04-02 | 4 | Jin David — Chief Financial Officer | Grant/award (A): 2,352 @ $1.70 | EDGAR |
| 2024-01-09 | 4 | ROSENWALD LINDSAY A MD — President, CEO & Chairman, Director, 10% owner | Purchase (P): 50,000 @ $2.38 | EDGAR |
| 2024-01-03 | 4 | Lorenz Kevin — Director | Grant/award (A): 3,333 @ $0 | EDGAR |
| 2024-01-03 | 4 | Lu Lucy — Director | Grant/award (A): 3,333 @ $0 | EDGAR |
| 2024-01-03 | 4 | ROSENWALD LINDSAY A MD — President, CEO & Chairman, Director, 10% owner | Grant/award (A): 216,465 @ $0 | EDGAR |
| 2024-01-03 | 4 | Klein Dov — Director | Grant/award (A): 6,666 @ $0 | EDGAR |
| 2024-01-03 | 4 | Harvey Jimmie — Director | Grant/award (A): 6,666 @ $0 | EDGAR |
| 2024-01-03 | 4 | Rowinsky Eric K — Director | Grant/award (A): 6,666 @ $0 | EDGAR |
| 2024-01-03 | 4 | Hoenlein Malcolm — Director | Grant/award (A): 3,333 @ $0 | EDGAR |
| 2024-01-03 | 4 | LOBELL J JAY — Director | Grant/award (A): 6,666 @ $0 | EDGAR |
| 2024-01-03 | 4 | WEISS MICHAEL S — See Remarks, Director, 10% owner | Grant/award (A): 216,465 @ $0 | EDGAR |
| 2023-12-22 | 4 | Jin David — Chief Financial Officer | Grant/award (A): 140,000 @ $0 | EDGAR |
Recent 8-K events — Fortress Biotech, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities | EDGAR |
| 2025-11-17 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=FBIO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →